Reliq Health Technologies Has Reached An Inflection Point

  • The company still saw 36% sequential growth despite Omicron headwind. CAD$2M run rate in December reflects CAD $24M annually; they are still on course to meet CAD$40M 2022 reaffirmed guidance.
  • The company has an enormous number of signed customers which is increasing on a weekly basis and with the Cognizant partnership, there is a chance to land whales.
  • Medical platform stocks should do well in this market, although so far they are sharing in the malaise.
  • Management argues they don’t need additional financing but we’re not entirely convinced here, although it’s entirely possible that option exercise ties them over to cash flow positive.
  • Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »